US 12,234,216 B2
Isotopologues salts, crystalline forms, stereoisomers, of methylone and ethylone and methods of use thereof
Samuel Clark, Miami Beach, FL (US); and Matthew Duncton, Las Vegas, NV (US)
Assigned to Terran Biosciences Inc., Miami Beach, FL (US)
Filed by Terran Biosciences Inc., Miami Beach, FL (US)
Filed on Dec. 28, 2022, as Appl. No. 18/147,071.
Application 18/147,071 is a continuation of application No. PCT/US2022/049027, filed on Nov. 4, 2022.
Claims priority of provisional application 63/276,539, filed on Nov. 5, 2021.
Claims priority of provisional application 63/280,071, filed on Nov. 16, 2021.
Claims priority of provisional application 63/280,073, filed on Nov. 16, 2021.
Claims priority of provisional application 63/280,075, filed on Nov. 16, 2021.
Claims priority of provisional application 63/283,027, filed on Nov. 24, 2021.
Claims priority of provisional application 63/311,874, filed on Feb. 18, 2022.
Claims priority of provisional application 63/320,654, filed on Mar. 16, 2022.
Claims priority of provisional application 63/326,774, filed on Apr. 1, 2022.
Claims priority of provisional application 63/326,776, filed on Apr. 1, 2022.
Claims priority of provisional application 63/326,782, filed on Apr. 1, 2022.
Claims priority of provisional application 63/326,792, filed on Apr. 1, 2022.
Claims priority of provisional application 63/367,445, filed on Jun. 30, 2022.
Claims priority of provisional application 63/388,840, filed on Jul. 13, 2022.
Claims priority of provisional application 63/377,328, filed on Sep. 27, 2022.
Prior Publication US 2023/0192642 A1, Jun. 22, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 317/58 (2006.01); A61K 31/36 (2006.01); A61P 25/18 (2006.01); A61P 25/22 (2006.01)
CPC C07D 317/58 (2013.01) [A61K 31/36 (2013.01); A61P 25/18 (2018.01); A61P 25/22 (2018.01); C07B 2200/13 (2013.01)] 14 Claims
 
1. A crystalline form of racemic 3,4-methylenedioxy-N-methylcathinone (methylone) hydrochloride (Form A), wherein the crystalline methylone hydrochloride (Form A) is characterized as having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at 7.5°±0.2 2-Theta, 10.3°±0.2 2-Theta, and 15.1±0.2 2-Theta as measured with Cu Kα radiation.